Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China flag China · Delayed Price · Currency is CNY
3.910
-0.040 (-1.01%)
Sep 10, 2026, 1:45 PM CST

SHE:300194 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,6301,6782,3082,5712,3782,388
Other Revenue
27.4560.1783.176.9444.2264.71
1,6571,7382,3912,6482,4222,453
Revenue Growth
-11.81%-27.31%-9.68%9.33%-1.28%3.58%
Cost of Revenue
1,0461,1311,1741,2811,066935.97
Gross Profit
611.52607.611,2181,3671,3551,517
Selling, General & Admin
385.41400.6804.891,0211,0921,217
Research & Development
118.66134.66153.22148.79142.89120.38
Other Operating Expenses
6.199.386.915.3116.2828.08
Operating Expenses
508.02550.92968.971,1821,2551,370
Operating Income
103.556.69248.55184.51100.24147.59
Interest Expense
-10.86-22.15-23.34-29.57-26.94-20.45
Interest & Investment Income
115.35168.16106.8109.4190.0774.46
Currency Exchange Gain (Loss)
-0.220.20.980.661.47-0.59
Other Non Operating Income (Expenses)
-6.78-0.66-0.45-0.85-1.4-1.76
EBT Excluding Unusual Items
200.99202.23332.54264.17163.44199.26
Impairment of Goodwill
-129.02-129.02--224.51-22.97-201.06
Gain (Loss) on Sale of Investments
-1.96-1.86-32.740.410.420.75
Gain (Loss) on Sale of Assets
-0.450.270.01220.654.850.31
Asset Writedown
-6.95-2.65-4.92-3.61-2.44-626.17
Other Unusual Items
8.1514.2817.333.2446.0734.93
Pretax Income
70.7683.24312.2290.36189.35-591.99
Income Tax Expense
11.486.7634.0355.95-11.4717.61
Earnings From Continuing Operations
59.2876.49278.17234.41200.82-609.59
Minority Interest in Earnings
0.370.511.67-2.543.79312.68
Net Income
59.6577279.84231.87204.61-296.91
Net Income to Common
59.6577279.84231.87204.61-296.91
Net Income Growth
-66.20%-72.48%20.69%13.32%--
Shares Outstanding (Basic)
1,3161,2831,1661,2201,2041,188
Shares Outstanding (Diluted)
1,3161,2831,1661,2201,2041,188
Shares Change
16.46%10.06%-4.46%1.40%1.34%2.10%
EPS (Basic)
0.050.060.240.190.17-0.25
EPS (Diluted)
0.050.060.240.190.17-0.25
EPS Growth
-70.98%-75.00%26.32%11.77%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
352.27203.8961.8113.3-43.6-155.91
Free Cash Flow Per Share
0.270.160.050.09-0.04-0.13
Dividend Per Share
0.0500.0700.0500.0500.050-
Dividend Growth
-28.57%40.00%0%0%0%-
Gross Margin
36.90%34.96%50.91%51.63%55.97%61.85%
Operating Margin
6.25%3.26%10.39%6.97%4.14%6.02%
Profit Margin
3.60%4.43%11.70%8.76%8.45%-12.10%
Free Cash Flow Margin
21.26%11.73%2.58%4.28%-1.80%-6.35%
EBITDA
304.79260.54446.01392.88284.11321.89
EBITDA Margin
18.39%14.99%18.65%14.84%11.73%13.12%
D&A For EBITDA
201.29203.86197.45208.37183.87174.29
EBIT
103.556.69248.55184.51100.24147.59
EBIT Margin
6.25%3.26%10.39%6.97%4.14%6.02%
Effective Tax Rate
16.23%8.12%10.90%19.27%--
Revenue as Reported
817.781,7382,3912,6482,4222,453
Advertising Expenses
-18.8924.052.440.480.5